JCR Pharmaceuticals Co., Ltd.

As of March 31, 2026, JCR Pharmaceuticals Co., Ltd. carries a market capitalization of 373.30M, placing it among publicly traded companies globally. Its enterprise value stands at 593.01M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

JCR Pharmaceuticals Co., Ltd.'s next confirmed earnings release is scheduled for October 29, 2026.

As of March 31, 2026, JCR Pharmaceuticals Co., Ltd. has 121.99M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, JCR Pharmaceuticals Co., Ltd. maintains a current ratio of 1.16, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, JCR Pharmaceuticals Co., Ltd.'s stock has declined approximately 13.87% over the past 52 weeks. The 50-day moving average sits at 2.82, while the 200-day moving average is 2.94.

As of March 31, 2026, JCR Pharmaceuticals Co., Ltd. holds 76.36M in cash and equivalents against 293.80M in total debt, resulting in a net debt position of 217.44M. Total book value stands at 255.91M, with working capital of 43.29M providing operational flexibility.

JCR Pharmaceuticals Co., Ltd.'s most recent stock split took place on September 29, 2020 with a 1:4 split ratio.